This browser doesn't support Spotify Web Player. Switch browsers or download Spotify for your desktop.

Gut podcast

By BMJ Group

Gut is a leading international journal in gastroenterology and hepatology. It has an established reputation for publishing first class clinical research of the alimentary tract, the liver, biliary tree and pancreas. Gut delivers up-to-date, authoritative, clinically oriented coverage of all areas in gastroenterology. Regular features include articles by leading authorities, reports on the latest treatments for diseases, reviews and commentaries. Subscribers to Gut also receive Frontline Gastroenterology (FG). In 2019, Gut received its highest Impact Factor of 19.819, placing it third in the category of Gastroenterology and Hepatology. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

  1. 1.
    Adipose tissue derived bacteria are associated with inflammation in obesity and type 2 diabetes10/19/2020
    19:20
  2. 2.
    Global burden of oesophageal and gastric cancer by histology and subsite in 201809/26/2020
    8:52
  3. 3.
    Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease08/13/2020
    13:02
  4. 4.
    Efficacy of FMT for patients with IBS in a randomised, double-blind, placebo-controlled study07/19/2020
    13:27
  5. 5.
    Infants born to mothers with IBD present with altered gut microbiome06/22/2020
    8:02
  6. 6.
    Mediterranean diet intervention alters the gut microbiome in older people05/31/2020
    14:54
  7. 7.
    Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus05/03/2020
    12:17
  8. 8.
    British Society of Gastroenterology guidance for management of IBD during the Covid-19 pandemic04/22/2020
    23:07
  1. 9.
    Global patterns and trends in colorectal cancer incidence in young adults03/29/2020
    6:27
  2. 10.
    Guidelines on the management of inflammatory bowel disease in adults11/21/2019
    9:28
  3. 11.
    European evidence-based guidelines on pancreatic cystic neoplasms08/20/2018
    13:27
  4. 12.
    Viral transfer during FMT linked to better outcomes in recurrent C. diff bacterial infections05/11/2018
    17:36
  5. 13.
    Colorectal cancer: research prioritisation needed in third most lethal malignancy worldwide03/15/2018
    19:42
  6. 14.
    Development of an FGF19-based chimeric molecule to promote fatty liver regeneration11/26/2017
    23:53
  7. 15.
    Feeding the microbiota: transducer of nutrient signals for the host10/29/2017
    23:52
  8. 16.
    Dietary emulsifiers directly alter human microbiota composition08/16/2017
    17:05
  9. 17.
    Faecal microbiota transplantation in clinical practice06/20/2017
    17:56
  10. 18.
    BMP-9 interferes with liver regeneration and promotes liver fibrosis05/31/2017
    16:48
  11. 19.
    A systematic review of isolated colonic Crohn's disease: the third IBD?02/27/2017
    17:04
  12. 20.
    Gut microbiome and liver diseases02/02/2017
    24:40
  13. 21.
    Antibiotics as deep modulators of gut microbiota: between good and evil.01/04/2017
    17:23
  14. 22.
    Asia-Pacific consensus on the management of gastro-oesophageal reflux disease10/19/2016
    23:15
  15. 23.
    Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma09/22/2016
    27:17
  16. 24.
    Live birth and adverse birth outcomes in women with ulcerative colitis and Crohn's disease06/17/2016
    13:01
  17. 25.
    GLP-1 based therapies: clinical implications for gastroenterologists05/24/2016
    22:51
  18. 26.
    Dysbiotic gut microbiota causes transmissible Crohn's disease-like ileitis03/23/2016
    15:37
  19. 27.
    Mesalazine and thymoquinone attenuate intestinal tumour development in mice03/08/2016
    19:05
  20. 28.
    Effects of bowel cleansing on the intestinal microbiota01/25/2016
    11:10
  21. 29.
    Development of an enhanced human gastrointestinal epithelial culture system08/28/2015
    22:10
  22. 30.
    Helicobacter pylori targets cancer-associated apical-junctional constituents06/16/2015
    14:08
  23. 31.
    Diagnosis and management of acute kidney injury in patients with cirrhosis05/29/2015
    13:15
  24. 32.
    Demonstration of the usefulness of epigenetic cancer risk prediction04/27/2015
    16:10
  25. 33.
    XIAP variants in male Crohn's disease02/10/2015
    27:33
  26. 34.
    Cell lineage distribution atlas reveals heterogeneous gland populations in the gastric antrum01/02/2015
    14:25
  27. 35.
    Classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease10/24/2014
    20:27
  28. 36.
    Update on basic and clinical aspects of eosinophilic oesophagitis09/25/2014
    25:38
  29. 37.
    AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition08/21/2014
    15:43
  30. 38.
    Besifovir versus entecavir in Asian patients with chronic hepatitis B08/15/2014
    9:29
  31. 39.
    Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea06/09/2014
    20:12
  32. 40.
    Recent advances in clinical practice challenges and opportunities in the management of obesity04/29/2014
    23:38
  33. 41.
    Amniotic stem cell treament for necrotic enterocolitis02/21/2014
    24:23
  34. 42.
    British Society of Gastroenterology guidelines on diagnosing and managing Barrett's oesophagus01/31/2014
    24:01
  35. 43.
    Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients11/29/2013
    19:20
  36. 44.
    A systematic approach to therapeutic target selection in oesophago-gastric cancer11/15/2013
    10:01
  37. 45.
    Gut podcast: Treatment of pancreatic fibrosis with siRNA10/22/2013
    13:15
  38. 46.
    Intra-tumoural stroma as a predictor of survival in patients with gastric cancer08/02/2013
    17:20
  39. 47.
    Probiotics in health and disease07/25/2013
    29:22
  40. 48.
    Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission07/25/2013
    18:55
  41. 49.
    mTNF reverse signalling induced by TNFα antagonists involves a GDF-1 dependent pathway04/24/2013
    26:21
  42. 50.
    Endoscopic improvement of mucosal lesions in patients with ileocolonic Crohn’s disease04/24/2013
    23:06
  43. 51.
    Bowel cancer screening in England02/21/2013
    20:58
  44. 52.
    PUFAS and neoplasms02/21/2013
    23:21
  45. 53.
    Cancer treatment induced gastrointestinal symptoms02/21/2013
    40:52
  46. 54.
    Bifidobacterium and gastrointestinal inflammation02/21/2013
    16:42
  47. 55.
    High-fat diet and gut microbiota02/21/2013
    10:28
  48. 56.
    Management of Helicobacter pylori infection02/21/2013
    30:17
  49. 57.
    Assessment of colorectal cancer molecular features02/21/2013
    21:10
  50. 58.
    Probiotic and postbiotic activity in health and disease02/21/2013
    15:30
  51. 59.
    NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease02/21/2013
    24:39
  52. 60.
    Outcomes of the Bowel Cancer Screening Programme in England02/21/2013
    20:58
  53. 61.
    Mucosal healing in inflammatory bowel disease02/21/2013
    21:22
  54. 62.
    Interleukin 13 and its role in gut defence and inflammation02/21/2013
    30:34
  55. 63.
    Revising the classification of acute pancreatitis02/21/2013
    31:07

Listen to Gut podcast now.

Listen to Gut podcast in full in the Spotify app